FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1897-1898 December 21, 2000 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Secondary cancer is an important complication of the treatment of childhood cancer. The occurrence of secondary acute myeloid leukemia (AML) after successful treatment of a variety of tumors^1,2,3 generally carries a poor prognosis. We report a case of secondary AML that followed treatment for acute monoblastic leukemia.

A 21-year-old woman had been treated when she was 18 years old for acute monoblastic leukemia subtype M5a according to the French–American–British (FAB) classification with cytarabine (cumulative dose, 36.2 g per square meter of body-surface area), etoposide (795 mg per square meter), thioguanine (2.58 g per square meter), doxorubicin (120 . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.